Analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will post $1.85 earnings per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Jazz Pharmaceuticals PLC’s earnings, with the highest EPS estimate coming in at $1.87 and the lowest estimate coming in at $1.83. Jazz Pharmaceuticals PLC reported earnings per share of $1.80 during the same quarter last year, which would suggest a positive year-over-year growth rate of 2.8%. The firm is scheduled to report its next quarterly earnings results after the market closes on Tuesday, August 8th.
On average, analysts expect that Jazz Pharmaceuticals PLC will report full-year earnings of $7.29 per share for the current fiscal year, with EPS estimates ranging from $7.18 to $7.40. For the next financial year, analysts expect that the company will post earnings of $8.84 per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Jazz Pharmaceuticals PLC.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing the consensus estimate of $1.42 by $0.01. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The business had revenue of $376.10 million for the quarter, compared to analyst estimates of $376.58 million. During the same period in the prior year, the business earned $2.26 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis.
A number of research firms have commented on JAZZ. Sanford C. Bernstein set a $176.00 price target on Jazz Pharmaceuticals PLC and gave the company a “market perform” rating in a research report on Monday, May 22nd. Leerink Swann set a $179.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Thursday, April 27th. Vetr raised Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price target for the company in a research report on Tuesday, June 6th. Deutsche Bank AG reaffirmed a “buy” rating and set a $176.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, July 4th. Finally, Piper Jaffray Companies set a $182.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the company’s stock. Jazz Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $182.56.
In related news, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $152.98, for a total value of $30,596.00. Following the sale, the executive vice president now owns 22,623 shares in the company, valued at approximately $3,460,866.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Suzanne Sawochka Hooper sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $160.00, for a total value of $400,000.00. Following the completion of the sale, the executive vice president now owns 37,149 shares in the company, valued at approximately $5,943,840. The disclosure for this sale can be found here. Insiders sold a total of 43,100 shares of company stock worth $6,645,820 in the last 90 days. 4.30% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of the company. US Bancorp DE increased its stake in Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 368 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 295 shares during the last quarter. Gargoyle Investment Advisor L.L.C. bought a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at $206,000. Janney Montgomery Scott LLC bought a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at $211,000. Finally, SG Americas Securities LLC increased its stake in Jazz Pharmaceuticals PLC by 13.0% in the second quarter. SG Americas Securities LLC now owns 1,384 shares of the specialty pharmaceutical company’s stock valued at $215,000 after buying an additional 159 shares during the last quarter. Institutional investors own 86.43% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://stocknewstimes.com/2017/08/18/zacks-brokerages-expect-jazz-pharmaceuticals-plc-jazz-will-post-earnings-of-1-85-per-share-updated.html.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 0.03% during midday trading on Wednesday, reaching $155.56. The company had a trading volume of 405,902 shares. The stock has a market capitalization of $9.34 billion, a price-to-earnings ratio of 23.51 and a beta of 1.10. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The company has a 50-day moving average price of $155.48 and a 200-day moving average price of $145.64.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Get a free copy of the Zacks research report on Jazz Pharmaceuticals PLC (JAZZ)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.
